POSTED: September 04, 2015

Oliver Sartor On Xofigo

Dr. Oliver Sartor, Tulane University Cancer Center, Comprehensive ClinicProstate Forum recently spoke with Dr. Oliver Sartor of Tulane School Of Medicine in Louisiana about Xofigo for men with metastatic castration-resistant prostate cancer. You can read the entire interview in Prostate Forum Volume 15 Number 8.

Prostate Forum asked: Can you tell us about the progression of your career and how you came to concentrate your efforts on advanced prostate cancer?

I did my Fellowship at the National Cancer Institute and then, after three years of research, joined Dr. Myers in 1990 and started to focus on prostate cancer. In 1993, I returned to my home state of Louisiana. I was on faculty at Harvard after Hurricane Katrina. I’m currently the Medical Director of the Cancer Center at Tulane University and continue to see prostate cancer patients.

What is castrate resistant prostate cancer?

A man has castrate resistant prostate cancer if there is evidence of progressive disease despite a level of testosterone below 50 nanogams per deciliter.

What is Xofigo’s place in the development of therapies for men with castrate-resistant prostate cancer that has metastasized to bone?

Xofigo is indicated very specifically for people with bone metastatic lesions. As the FDA has stated, Xofigo should not be used in patients with visceral disease, or evidence of liver or lung lesions. I don’t think it should be used in patients with a large volume of lymph node involvement. Xofigo is best used in men with bone-predominate castrate resistant prostate cancer.
Treating with Xofigo is very similar to getting a bone scan that is therapeutic, not diagnostic. Instead of a diagnostic isotope, we use a therapeutic isotope, which just targets to where the bone lesions are.
In the prospective randomized trial that led to Xofigo’s FDA-approval, patients were symptomatic. In these patients, it demonstrated a prolongation of survival.

Who administers radium?

Someone in nuclear medicine or radiation oncology must administer Xofigo. It has to be someone licensed for the administration of an isotope. It can’t be a family practice doctor.

Do patients generally have any problems getting Xofigo covered by insurance?

No. It is FDA-approved.

Leave A Comment